Publications and Presentations

Filter By:

ARRY-380

04/01/2012

American Association for Cancer Research Annual Meeting

ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice

V. Dinkel, et al.

ARRY-614

03/09/2012

International Congress on Targeted Anticancer Therapies

ARRY-614, a Dual p38/Tie2 Inhibitor for Myelodysplastic Syndromes: Overview of the Phase 1 Experience

S. L. Winski, et al.

Binimetinib

01/20/2012

Gastrointestinal Cancers Symposium

A Phase 1 Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer

RS Finn, et al.

Motolimod

01/15/2012

Clinical Cancer Research

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC

Lu H, Dietsch GN, et al

ARRY-614

12/11/2011

American Society of Hematology Annual Meeting

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes

R. Komrokji, et al.

Filanesib

12/11/2011

American Society of Hematology Annual Meeting

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma

S. Lonial, M.D. et al.

Filanesib

12/10/2011

American Society of Hematology Annual Meeting

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

J.J. Shah, MD, et al.

ARRY-797

11/15/2011

Circulation

Inhibition of Site Specific Phosphorylation of Retinoblastoma Protein by a p38 Inhibitor Decreases Apoptosis, Improves Survival and Prevents Cardiomyopathy Caused by a Mutation in LMNA gene

Saqib et al

Ipatasertib

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues

Y. Yan, et al.

ARRY-380

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

ARRY-380, a Selective HER2 Inhibitor: From Drug Design to Clinical Evaluation

S. L. Moulder, et al.